Alumis Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALMS Nasdaq 2834 www.alumis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alumis Inc.

Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Feb 7th, 2026 1:03 pm
Alumis to Participate in Upcoming February Investor Conferences - Feb 5th, 2026 6:05 am
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - Feb 3rd, 2026 8:06 am
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Jan 30th, 2026 7:48 am
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - Jan 19th, 2026 6:45 am
Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise - Jan 18th, 2026 6:09 pm
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million - Jan 17th, 2026 12:06 pm
Staar Surgical, Alumis, and More Stocks See Action From Activist Investors - Jan 16th, 2026 6:39 pm
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)’s Price Target To $40 From $20, Reiterates Buy Rating - Jan 15th, 2026 9:35 am
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Jan 9th, 2026 2:05 pm
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Strong Share Price Momentum - Jan 8th, 2026 1:13 am
Alumis Announces Pricing of Upsized Public Offering of Common Stock - Jan 7th, 2026 8:52 pm
Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight - Jan 7th, 2026 3:31 pm
ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies - Jan 7th, 2026 9:52 am
Should You Chase the Rally in Alumis Stock Today? - Jan 7th, 2026 9:35 am
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - Jan 6th, 2026 3:32 pm
Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis - Jan 6th, 2026 2:29 pm
Alumis Announces Proposed Public Offering of Common Stock - Jan 6th, 2026 2:12 pm
Wall Street Consolidates, Driving Muted Premarket Action for US Equity Futures - Jan 6th, 2026 7:16 am
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program - Jan 6th, 2026 5:00 am